Pfizer Inc v. Teva Pharmaceuticals USA Inc.
1:08-cv-00237
Overview
Parties
Defendant
Teva Pharmaceuticals USA Inc. Operating Company
Represented By
0 Attorneys ListedWarner-Lambert Company NPE (Individual / Inventor)
Represented By
1 Attorneys ListedReed Smith LLP
1201 Market Street, Suite 1500
Pfizer Inc Operating Company
Represented By
1 Attorneys ListedReed Smith LLP
1201 Market Street, Suite 1500
Plaintiff
Warner-Lambert Export Ltd. Operating Company
Represented By
1 Attorneys ListedReed Smith LLP
1201 Market Street, Suite 1500
Warner-Lambert Company LLC Operating Company
Represented By
1 Attorneys ListedReed Smith LLP
1201 Market Street, Suite 1500
Pfizer Ireland Pharmaceuticals Operating Company
Represented By
1 Attorneys ListedReed Smith LLP
1201 Market Street, Suite 1500
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 2 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | US 5,273,995 A Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 38,418,789 A | US Continuation / Sibling | View Official Patent → |
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US5273995
[R-(R*R*)]-2-(4-fluorophenyl)-Ξ²,Ξ΄-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino) carbonyl]- 1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof
|
Filed: 1991-02-26
Issued: 1993-12-28
|
Expired (Term Ended)
Expires: 2011-02-26
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred β Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.
Standard Statutory Term β No obviousness-type double patenting truncation noted.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).